National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Brodalumab (Kyntheum®) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.


NCPE Assessment Process Ongoing
Rapid review received 25/07/2017
Rapid review completed 29/08/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended at submitted price

The HSE has approved reimbursement following confidential price negotiations January 2018.